Miething C - Search Results

1

Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model.

Kreutmair S, Klingeberg C, Poggio T, Andrieux G, Keller A, Miething C, Follo M, Pfeifer D, Shoumariyeh K, Lengerke C, Gonzalez-Menendez I, Fend F, Zeiser R, Turner SD, Quintanilla-Martinez L, Boerries M, Duyster J, Illert AL. Kreutmair S, et al. Among authors: miething c. Leukemia. 2020 Dec;34(12):3242-3255. doi: 10.1038/s41375-020-0789-x. Epub 2020 Mar 17. Leukemia. 2020. PMID: 32203142 Free PMC article.

2

Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Bai RY, et al. Among authors: miething c. Blood. 2000 Dec 15;96(13):4319-27. Blood. 2000. PMID: 11110708 Free article.

3

Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.

Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J, Peschel C. Decker T, et al. Among authors: miething c. Leukemia. 2002 Mar;16(3):327-34. doi: 10.1038/sj.leu.2402389. Leukemia. 2002. PMID: 11896535

4

Effects of imatinib on bone marrow engraftment in syngeneic mice.

Hoepfl J, Miething C, Grundler R, Götze KS, Peschel C, Duyster J. Hoepfl J, et al. Among authors: miething c. Leukemia. 2002 Sep;16(9):1584-8. doi: 10.1038/sj.leu.2402679. Leukemia. 2002. PMID: 12200667

5

Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).

Ouyang T, Bai RY, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J. Ouyang T, et al. Among authors: miething c. J Biol Chem. 2003 Aug 8;278(32):30028-36. doi: 10.1074/jbc.M300883200. Epub 2003 May 14. J Biol Chem. 2003. PMID: 12748172 Free article.

6

The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.

Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, von Schilling C, Morris SW, Peschel C, Duyster J. Miething C, et al. Oncogene. 2003 Jul 24;22(30):4642-7. doi: 10.1038/sj.onc.1206575. Oncogene. 2003. PMID: 12879008

7

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.

Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J. Miething C, et al. Leukemia. 2003 Sep;17(9):1695-9. doi: 10.1038/sj.leu.2403040. Leukemia. 2003. PMID: 12970766

8

Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.

van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE. van der Kuip H, et al. Among authors: miething c. Leuk Res. 2004 Apr;28(4):405-8. doi: 10.1016/j.leukres.2003.08.012. Leuk Res. 2004. PMID: 15109541

9

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

Grundler R, Miething C, Thiede C, Peschel C, Duyster J. Grundler R, et al. Among authors: miething c. Blood. 2005 Jun 15;105(12):4792-9. doi: 10.1182/blood-2004-11-4430. Epub 2005 Feb 17. Blood. 2005. PMID: 15718420 Free article.

10

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster J. Miething C, et al. Leukemia. 2006 Apr;20(4):650-7. doi: 10.1038/sj.leu.2404151. Leukemia. 2006. PMID: 16482207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters